Skip to main content
OpenTrials
Completed

NCT Number: NCT04897750

Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures

This is a prospective non-randomized, open-label, single dose (and a second dose if needed), PK study in 25 children age 1-17 years. The proposed number of study participants by subset is: 8 paediatric participants 1-2 years; 8 paediatric participants >2-6 years and 9 paediatric participants >6-17 years.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Anæstesi- og Operationsafdelingen 4013 Juliane Marie Centeret

Copenhagen, Region H, 2100, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Paediatric participants, age 1-17 years at the day of the surgical procedure
  • Planned for elective surgical procedures (e.g. hernia, orchiopexy, gastroscopy, cystoscopy)
  • ASA (American Society of Anaesthesiologists) physical status classification system score 1-2 as determined by investigator
  • Planned for induction of anaesthesia by an intravenous anaesthetic agent, requiring placement of peripheral venous catheter immediately prior to the surgical procedure
  • Needs premedication before induction of anaesthesia as determined by investigator
  • Informed consent by the legally acceptable representative(s)
  • The legally acceptable representative(s) and patients 15-17 years must be able to understand and speak local language
  • A female participant who has onset of menarche is eligible to participate if she is not pregnant, not breastfeeding and agree to follow the contraceptive guidance during the treatment period for at least 7 days after administration of study treatment.

Exclusion criteria

  • Ex-premature infant (born <37 weeks AND less than 60 weeks post conceptual age at the day of the surgical procedure)
  • Mental retardation
  • Abnormal nasal cavity or nasal obstruction
  • Clinical contraindications to narcotic analgesia including head injury or any condition that can in the opinion of the investigator, deteriorate safety and well-being of the participants, influence PK data or optimal participation in the trial
  • Medical history including substance or alcohol abuse
  • Has received treatment with sufentanil and/or ketamine during the last 72 hours prior to surgery
  • Has planned perioperative administration of sufentanil and/or ketamine
  • Has or is suspected of having a family or personal history of malignant hyperthermia
  • Has or is suspected of having allergies to ketamine or sufentanil

Treatment and study plan

CT001

Combination Product

Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.

Primary outcomes

  1. Total absorption over time

    Time frame: 0 - 120 minutes

    Area under the concentration vs time curve

  2. Maximum absorption

    Time frame: 0 - 120 minutes

    Peak concentration (Cmax)

  3. Distribution

    Time frame: 120 - 240 minutes

    Volumen of distribution (Vd)

  4. Elimination

    Time frame: 120 - 240 minutes

    Half life (T½)

  5. Elimination

    Time frame: 120 - 240 minutes

    Clearance,

Secondary outcomes

  1. Analgetic effect

    Time frame: 0 - 1 hour

    pain intensity by age-appropriate scale in relation to the placement of peripheral venous catheter

  2. Sedation

    Time frame: 0 - 1 hour

    Assessment of sedation at the time of placement of the peripheral venous catheter using the University of Michigan Sedation Score

  3. Feasibility, (Acceptance of intranasal administration)

    Time frame: 0- 4 hours

    Acceptance of the intranasal route of administration by the child, assessed by the child or legally acceptable representative or health care provider.

Sponsors and collaborators

Lead sponsor

Cessatech A/S

Industry

Registry information

Official study title

Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures.

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
May 21, 2021
Registry last updated
Aug 18, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.